This study is evaluating the safety and effectiveness of investigational drug, Ocrelizumab, in patients with relapsing remitting Multiple Sclerosis (MS) who have failed to respond to one or more treatments. <br><br>Patients will receive one infusion of 300mg Ocrelizumab at the baseline visit and at 2 weeks, and will receive an infusion of 600mg Ocrelizumab at weeks 24, 48 and 72. Patients will be in the study for up to 2 years.
- Trial ID:
- Charles R Smith, MD
- Be 18 years of age or older
- Have been diagnosed with the relapsing remitting form of MS
- Have failed to respond to at least one previous treatment for MS
- Agree to use at least two forms of contraception during the study and for at least 24 weeks after the last dose of study drug
- Meet all other eligibility criteria
- Have a history of primary progressive multiple sclerosis (PPMS), progressive relapsing multiple sclerosis (PRMS), or secondary progressive multiple sclerosis (SPMS)
- Be unable to complete an MRI
- Have other neurological disorders
- Ocrelizumab is a type of drug called a monoclonal antibody that acts like your body’s immune system, and attaches to certain cells to attack germs and illnesses in the body. Ocrelizumab attaches to certain types of B cells that are thought to play a role in MS. Ocrelizumab is an investigational drug that has not been approved by the US Food and Drug Administration (FDA).